BACKGROUND

Hemophilia A is a genetic bleeding disorder caused by a deficiency in factor VIII (FVIII). FVIII maintains bleeding homeostasis within the body through its dose-dependent clotting mechanism. The extent of the disease—either mild, moderate, or severe—depends on the amount of available FVIII in the blood. Patients with severe disease (FVIII <1%) bleed into joints and muscles which may lead to long-term complications such as pain, joint damage, or joint replacements. 1

Treatment of Hemophilia A involves replacing FVIII through either on-demand or prophylactic infusions. While on-demand treatment is infusates at the time of a bleed to stop the event, prophylactic therapy is given on a routine basis as prevention. 2 Prophylactic therapy is utilized in those with disease severity as recommended by the Medical and Scientific Advisory Council to maintain FVIII levels above 1%, reducing bleeding and joint damage. 2

FVIII products are either purified concentrates of human plasma (plasma-derived) or genetically engineered using recombinant DNA technology such as PEGylation and fragment-crystallization (Fc) immunoglobulin protein fusion introduced FVIII products with a half-life of 1.5 to 1.8 times that of standard therapies. These extended half-life (EHL) products maintain FVIII levels with an infusion frequency of once to twice weekly. 3

While indirect comparisons exist between clinical trial data of standard and extended therapies, there is limited real-world patient data directly comparing the outcomes of these products. 4

OBJECTIVES

To conduct a retrospective analysis comparing the efficacy, safety, cost, and factor utilization, of patients with hemophilia A taking an FDA approved EHL or SHL FVIII product for prophylactic therapy.

METHODS

AllianceRx Walgreens Prime specialty pharmacy records of patients taking an FDA approved SHL or EHL FVIII product for the prophylactic treatment of hemophilia A were retrospectively reviewed from January 1, 2017 to December 31, 2018. Data was collected from pharmacy dispensing records, clinical patient management applications, and chart notes provided from Hemophilia AllianceRx Walgreens Prime specialty pharmacy records of patients taking an FDA approved SHL FVIII product for prophylactic therapy. Data was collected from pharmacy dispensing records of patients taking an FDA approved SHL FVIII product for prophylactic therapy.

AllianceRx Walgreens Prime specialty pharmacy records of patients taking an FDA approved SHL or EHL FVIII product for the prophylactic treatment of hemophilia A were retrospectively reviewed from January 1, 2017 to December 31, 2018. Data was collected from pharmacy dispensing records, clinical patient management applications, and chart notes provided from Hemophilia AllianceRx Walgreens Prime specialty pharmacy records of patients taking an FDA approved SHL FVIII product for prophylactic therapy. Data was collected from pharmacy dispensing records of patients taking an FDA approved SHL FVIII product for prophylactic therapy.

AllianceRx Walgreens Prime specialty pharmacy records of patients taking an FDA approved SHL or EHL FVIII product for the prophylactic treatment of hemophilia A were retrospectively reviewed from January 1, 2017 to December 31, 2018. Data was collected from pharmacy dispensing records, clinical patient management applications, and chart notes provided from Hemophilia AllianceRx Walgreens Prime specialty pharmacy records of patients taking an FDA approved SHL FVIII product for prophylactic therapy. Data was collected from pharmacy dispensing records of patients taking an FDA approved SHL FVIII product for prophylactic therapy.

AllianceRx Walgreens Prime specialty pharmacy records of patients taking an FDA approved SHL or EHL FVIII product for the prophylactic treatment of hemophilia A were retrospectively reviewed from January 1, 2017 to December 31, 2018. Data was collected from pharmacy dispensing records, clinical patient management applications, and chart notes provided from Hemophilia AllianceRx Walgreens Prime specialty pharmacy records of patients taking an FDA approved SHL FVIII product for prophylactic therapy. Data was collected from pharmacy dispensing records of patients taking an FDA approved SHL FVIII product for prophylactic therapy.

AllianceRx Walgreens Prime specialty pharmacy records of patients taking an FDA approved SHL or EHL FVIII product for the prophylactic treatment of hemophilia A were retrospectively reviewed from January 1, 2017 to December 31, 2018. Data was collected from pharmacy dispensing records, clinical patient management applications, and chart notes provided from Hemophilia AllianceRx Walgreens Prime specialty pharmacy records of patients taking an FDA approved SHL FVIII product for prophylactic therapy. Data was collected from pharmacy dispensing records of patients taking an FDA approved SHL FVIII product for prophylactic therapy.

AllianceRx Walgreens Prime specialty pharmacy records of patients taking an FDA approved SHL or EHL FVIII product for the prophylactic treatment of hemophilia A were retrospectively reviewed from January 1, 2017 to December 31, 2018. Data was collected from pharmacy dispensing records, clinical patient management applications, and chart notes provided from Hemophilia AllianceRx Walgreens Prime specialty pharmacy records of patients taking an FDA approved SHL FVIII product for prophylactic therapy. Data was collected from pharmacy dispensing records of patients taking an FDA approved SHL FVIII product for prophylactic therapy.

AllianceRx Walgreens Prime specialty pharmacy records of patients taking an FDA approved SHL or EHL FVIII product for the prophylactic treatment of hemophilia A were retrospectively reviewed from January 1, 2017 to December 31, 2018. Data was collected from pharmacy dispensing records, clinical patient management applications, and chart notes provided from Hemophilia AllianceRx Walgreens Prime specialty pharmacy records of patients taking an FDA approved SHL FVIII product for prophylactic therapy. Data was collected from pharmacy dispensing records of patients taking an FDA approved SHL FVIII product for prophylactic therapy.

AllianceRx Walgreens Prime specialty pharmacy records of patients taking an FDA approved SHL or EHL FVIII product for the prophylactic treatment of hemophilia A were retrospectively reviewed from January 1, 2017 to December 31, 2018. Data was collected from pharmacy dispensing records, clinical patient management applications, and chart notes provided from Hemophilia AllianceRx Walgreens Prime specialty pharmacy records of patients taking an FDA approved SHL FVIII product for prophylactic therapy. Data was collected from pharmacy dispensing records of patients taking an FDA approved SHL FVIII product for prophylactic therapy.